¼¼°èÀÇ ÇÇÇÏ ¸é¿ª±Û·ÎºÒ¸° ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Çâ, ¾÷°è ºÐ¼® : Á¦Ç°º°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº° - ½ÃÀå ¿¹Ãø(2025-2034³â)
Subcutaneous Immunoglobulin Market Size, Share, Trends, & Industry Analysis Report By Product (IgG, IgA, and IgM), By Application, By End Use, and By Region - Market Forecast, 2025-2034
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é ÇÇÇÏ ¸é¿ª±Û·ÎºÒ¸° ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 267¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼´Â ÇöÀç ½ÃÀå ¿ªÇÐÀÇ »ó¼¼ ÀλçÀÌÆ®¿Í ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ °üÇÑ ºÐ¼®À» Á¦°øÇϰí ÀÖ½À´Ï´Ù.
ÇÇÇϸ鿪±Û·ÎºÒ¸°(SCIg)Àº ¸é¿ª°áÇÌÁõ ȯÀÚÀÇ ¸é¿ªÃ¼°è¸¦ ¾ÈÁ¤ÀûÀ¸·Î À¯ÁöÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â Ç×ü¸¦ ÇÇÇÏ·Î Åõ¿©ÇÏ´Â Ä¡·á¹ýÀÔ´Ï´Ù. ÀÌ ½ÃÀåÀº SCIg°¡ ȯÀÚ¿¡°Ô Á¦°øÇÏ´Â ÆíÀǼº°ú ÀÚÀ²¼º¿¡ ÈûÀÔ¾î ÀçÅà ġ·á·ÎÀÇ ÀüȯÀÌ ÁøÇàµÊ¿¡ µû¶ó È®´ëµÇ°í ÀÖ½À´Ï´Ù. º´¿ø¿¡ ÀÇÁ¸ÇÏ´Â ¼ö¾×°ú ´Þ¸® SCIg´Â Àͼ÷ÇÑ È¯°æ¿¡¼ Ä¡·á¸¦ °ü¸®ÇÒ ¼ö ÀÖÀ¸¸ç, ÀæÀº º´¿ø ¹æ¹®¿¡ ´ëÇÑ ºÎ´ãÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ À¯¿¬¼ºÀº Ä¡·á ¼øÀÀµµ¸¦ ³ôÀ̰í ȯÀÚÀÇ Àü¹ÝÀûÀÎ ¸¸Á·µµ¿Í »îÀÇ ÁúÀ» Çâ»ó½ÃÄÑ SCIg°¡ ¹Ù¶÷Á÷ÇÑ ÇüÅÂÀÇ ¸é¿ª±Û·ÎºÒ¸° Ä¡·áÁ¦·Î¼ÀÇ ¿ªÇÒÀ» °ÈÇÕ´Ï´Ù.
ÇÇÇÏ ¸é¿ª±Û·ÎºÒ¸° ½ÃÀåÀº Àü´Þ ÀåÄ¡ ¹× ÁÖÀÔ ±â¼úÀÇ Áö¼ÓÀûÀÎ Çõ½ÅÀ¸·Î ÀÎÇØ ´õ¿í °ßÀεǰí ÀÖ½À´Ï´Ù. ÈÞ´ë¿ë ÆßÇÁ, ÇÁ¸®ÇÊµå ½Ã¸°Áö µî »ç¿ëÇϱ⠽¬¿î ½Ã½ºÅÛÀÇ °³¹ß·Î Åõ¾à °úÁ¤ÀÌ °£¼ÒÈµÇ¾î ´õ ¸¹Àº ȯÀÚÃþÀÌ ½±°Ô Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº Ä¡·áÀÇ º¹À⼺°ú ½Ã°£À» ÁÙÀ̰í, µµÀÔ À庮À» ÃÖ¼ÒÈÇÏ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ±â¼úÀÇ ¹ßÀüÀº ƯÈ÷ SCIgÀÇ Ä¡·á ¹üÀ§¸¦ È®ÀåÇÏ°í ÆíÀǼº°ú È¿À²¼º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ¸Â¹°·Á Àå±âÀûÀÎ ¸é¿ª¿ä¹ý °ü¸®¿¡¼ SCIgÀÇ Á¸Àç°¨À» °ÈÇϰí ÀÖ½À´Ï´Ù.
ÇÇÇÏ ¸é¿ª±Û·ÎºÒ¸° ½ÃÀå : ºÐ¼® °³¿ä
Á¦Ç°º°·Î´Â IgG°¡ 2024³â ¸ÅÃâ Á¡À¯À²À» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. IgG´Â ±¤¹üÀ§ÇÑ ¿ø¹ß¼º ¹× ÀÌÂ÷¼º ¸é¿ª°áÇÌÁõ Ä¡·á¿¡ È¿°úÀûÀ¸·Î »ç¿ëµÇ´Â ÁÖ¿ä ¸é¿ª±Û·ÎºÒ¸°ÀÇ ¾ÆÀ̼ÒÀ¯ÇüÀ̱⠶§¹®ÀÔ´Ï´Ù.
¿ëµµº°·Î´Â ÈÄõ¼º ¸é¿ª °áÇÌÀ» À¯¹ßÇÒ ¼ö ÀÖ´Â ¾Ï, ÀÚ°¡¸é¿ªÁúȯ µîÀÇ ÁúȯÀÌ Àü ¼¼°è¿¡¼ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ÀÌÂ÷¼º ¸é¿ª °áÇÌ ºÐ¾ßÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
ºÏ¹Ì´Â Á¤±³ÇÑ ÀÇ·á ½Ã½ºÅÛ°ú ÷´Ü Ä¡·á ¼Ö·ç¼ÇÀÇ ºü¸¥ ÅëÇÕÀ¸·Î 2024³â SCIG ¼¼°è ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀº ´ë±Ô¸ð ÀÇ·á ÅõÀÚ, Áúº´¿¡ ´ëÇÑ ÀÎ½Ä °³¼±, ÃֽŠġ·á¹ý¿¡ ´ëÇÑ Á¢±Ù¼º Çâ»óÀ¸·Î ÀÎÇØ °¡Àå ³ôÀº ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¼¼°èÀÇ ÁÖ¿ä ±â¾÷¿¡´Â Baxter, Biotest, CSL Behring, GC Biopharma USA, Inc., Grifols, Kamada Ltd., LFB, Nufactor, Octapharma, Takeda µîÀÌ ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼·Ð
Á¦2Àå °³¿ä
Á¦3Àå ºÐ¼® ¹æ¹ý
Á¦4Àå ¼¼°èÀÇ ÇÇÇÏ ¸é¿ª±Û·ÎºÒ¸° ½ÃÀå ÀλçÀÌÆ®
½ÃÀå ½º³À¼ô
ÇÇÇÏ ¸é¿ª±Û·ÎºÒ¸° ½ÃÀå ¿ªÇÐ
ÃËÁø¿äÀΰú ±âȸ
¸é¿ª ºÎÀü ÁúȯÀÇ À¯º´·ü Áõ°¡
Á¦Á¦ ±â¼úÀÇ Áøº¸
¾ïÁ¦¿äÀΰú °úÁ¦
PESTLE ºÐ¼®
ÇÇÇÏ ¸é¿ª±Û·ÎºÒ¸° ½ÃÀåÀÇ µ¿Çâ
¹ë·ùüÀÎ ºÐ¼®
Á¦5Àå ÇÇÇÏ ¸é¿ª±Û·ÎºÒ¸° ½ÃÀå : Á¦Ç° À¯Çüº°
ÁÖ¿ä Á¶»ç °á°ú
¼·Ð
IgG
IgA
IgM
Á¦6Àå ÇÇÇÏ ¸é¿ª±Û·ÎºÒ¸° ½ÃÀå : ¿ëµµº°
ÁÖ¿ä Á¶»ç °á°ú
¼·Ð
¿ø¹ß¼º ¸é¿ª ºÎÀüÁõ
2Â÷¼º ¸é¿ª ºÎÀüÁõ
Á¦7Àå ÇÇÇÏ ¸é¿ª±Û·ÎºÒ¸° ½ÃÀå : ÃÖÁ¾ ¿ëµµº°
ÁÖ¿ä Á¶»ç °á°ú
¼·Ð
º´¿ø
ÀçÅà ÀÇ·á
Áø·á¼Ò
±âŸ
Á¦8Àå ÇÇÇÏ ¸é¿ª±Û·ÎºÒ¸° ½ÃÀå : Áö¿ªº°
ÁÖ¿ä ºÐ¼® °á°ú
¼·Ð
ÇÇÇÏ ¸é¿ª±Û·ÎºÒ¸° ½ÃÀå ºÐ¼® : Áö¿ªº°(2020-2034³â)
ºÏ¹Ì
ºÏ¹Ì : Á¦Ç° À¯Çüº°, Áö¿ªº°(2020-2034³â)
ºÏ¹Ì : ¿ëµµº°, Áö¿ªº°(2020-2034³â)
ºÏ¹Ì : ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°(2020-2034³â)
¹Ì±¹
ij³ª´Ù
À¯·´
À¯·´ : Á¦Ç° À¯Çüº°, Áö¿ªº°(2020-2034³â)
À¯·´ : ¿ëµµº°, Áö¿ªº°(2020-2034³â)
À¯·´ : ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°(2020-2034³â)
¿µ±¹
ÇÁ¶û½º
µ¶ÀÏ
ÀÌÅ»¸®¾Æ
½ºÆäÀÎ
³×´ú¶õµå
·¯½Ã¾Æ
±âŸ À¯·´
¾Æ½Ã¾ÆÅÂÆò¾ç
¾Æ½Ã¾ÆÅÂÆò¾ç : Á¦Ç° À¯Çüº°, Áö¿ªº°(2020-2034³â)
¾Æ½Ã¾ÆÅÂÆò¾ç : ¿ëµµº°, Áö¿ªº°(2020-2034³â)
¾Æ½Ã¾ÆÅÂÆò¾ç : ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°(2020-2034³â)
Áß±¹
Àεµ
¸»·¹À̽þÆ
ÀϺ»
Àεµ³×½Ã¾Æ
Çѱ¹
È£ÁÖ
±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : Á¦Ç° À¯Çüº°, Áö¿ªº°(2020-2034³â)
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¿ëµµº°, Áö¿ªº°(2020-2034³â)
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°(2020-2034³â)
»ç¿ìµð¾Æ¶óºñ¾Æ
¾Æ¶ø¿¡¹Ì¸®Æ®
À̽º¶ó¿¤
³²¾ÆÇÁ¸®Ä«°øÈ±¹
±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
¶óƾ¾Æ¸Þ¸®Ä«
¶óƾ¾Æ¸Þ¸®Ä« : Á¦Ç° À¯Çüº°, Áö¿ªº°(2020-2034³â)
¶óƾ¾Æ¸Þ¸®Ä« : ¿ëµµº°, Áö¿ªº°(2020-2034³â)
¶óƾ¾Æ¸Þ¸®Ä« : ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°(2020-2034³â)
¸ß½ÃÄÚ
ºê¶óÁú
¾Æ¸£ÇîÆ¼³ª
±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
Á¦9Àå °æÀï ±¸µµ
È®´ë¿Í Àμö ºÐ¼®
Á¦ÈÞ/Çù¾÷/ÇÕÀÇ/°ø°³
Á¦10Àå ±â¾÷ °³¿ä
Baxter
Biotest
CSL Behring
GC Biopharma USA, Inc.
Grifols
Kamada Ltd.
LFB
Nufactor
Octapharma
Takeda
KSA
The subcutaneous immunoglobulin market size is expected to reach USD 26.78 billion by 2034, according to a new study by Polaris Market Research. The report "Subcutaneous Immunoglobulin Market Share, Size, Trends, Industry Analysis Report: By Product (IgG, IgA, and IgM), By Application, By End Use, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Subcutaneous immunoglobulin (SCIg) is a therapy administered under the skin to deliver antibodies that help maintain immune system stability in patients with immunodeficiency disorders. This market is witnessing expansion due to the growing shift toward home-based treatments, driven by the convenience and autonomy that SCIg offers patients. Unlike hospital-dependent infusions, SCIg enables individuals to manage their therapy in familiar settings, reducing the burden of frequent clinical visits. This flexibility improves treatment adherence and also enhances overall patient satisfaction and quality of life, reinforcing SCIg's role as a preferred mode of immunoglobulin therapy.
The subcutaneous immunoglobulin market is further driven by the continuous innovation in delivery devices and infusion technologies. The development of user-friendly systems, such as portable pumps and pre-filled syringes, is simplifying the administration process and making therapy more accessible to a wider patient base. These advancements reduce the complexity and time associated with treatment, minimizing barriers to adoption. Technological progress is especially expanding the therapeutic reach of SCIg and strengthening its presence in long-term immunotherapy management by aligning with the growing demand for convenience and efficiency.
Subcutaneous Immunoglobulin Market Report Highlights
In terms of product, the IgG dominated the revenue share in 2024, as it is the primary immunoglobulin isotype used to effectively treat a wide range of primary and secondary immunodeficiency disorders.
Based on application, the secondary immunodeficiency segment growth is driven by the increasing global incidence of conditions like cancer and autoimmune diseases, which can cause acquired immune deficiencies.
North America led the global SCIG market in 2024, fueled by its refined healthcare systems and rapid integration of advanced therapeutic solutions.
Asia Pacific region is anticipated to register the highest growth rate, propelled by major healthcare investments, greater disease awareness, and improved access to modern treatments.
A few global key market players include Baxter; Biotest; CSL Behring; GC Biopharma USA, Inc.; Grifols; Kamada Ltd.; LFB; Nufactor; Octapharma; and Takeda.
Polaris Market Research has segmented the market report on the basis product type, application, end use, and region:
By Product Type Outlook (Revenue, USD Billion, 2020-2034)
IgG
IgA
IgM
By Application Outlook (Revenue, USD Billion, 2020-2034)
Primary Immunodeficiency Disease
Secondary Immunodeficiency Disease
By End Use (Revenue, USD Billion, 2020-2034)
Hospitals
Homecare
Clinics
Others
By Regional Outlook (Revenue, USD Billion, 2020-2034)
North America
US
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Vietnam
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Table of Contents
1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
3. Research Methodology
3.1. Overview
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. Subcutaneous Immunoglobulin Market Insights
4.1. Subcutaneous Immunoglobulin Market - Market Snapshot
4.2. Subcutaneous Immunoglobulin Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Growth in Prevalence of Immunodeficiency Diseases
4.2.1.2. Rising Advancement in Formulation Technology
4.2.2. Restraints and Challenges
4.2.2.1. High Treatment Cost
4.2.3. Public opinion and privacy legal precedents
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Subcutaneous Immunoglobulin Market Trends
4.6. Value Chain Analysis
5. Subcutaneous Immunoglobulin Market, By Product Type
5.1. Key Findings
5.2. Introduction
5.2.1. Subcutaneous Immunoglobulin Market, By Product Type, by Region, 2020-2034 (USD Billion)
5.3. IgG
5.3.1. Subcutaneous Immunoglobulin Market, by IgG, by Region, 2020-2034 (USD Billion)
5.4. IgA
5.4.1. Subcutaneous Immunoglobulin Market, by IgA, by Region, 2020-2034 (USD Billion)
5.5. IgM
5.5.1. Subcutaneous Immunoglobulin Market, by IgM, by Region, 2020-2034 (USD Billion)
6. Subcutaneous Immunoglobulin Market, By Application
6.1. Key Findings
6.2. Introduction
6.2.1. Subcutaneous Immunoglobulin Market, By Application, by Region, 2020-2034 (USD Billion)
6.3. Primary Immunodeficiency Disease
6.3.1. Subcutaneous Immunoglobulin Market, by Primary Immunodeficiency Disease, by Region, 2020-2034 (USD Billion)
6.4. Secondary Immunodeficiency Disease
6.4.1. Subcutaneous Immunoglobulin Market, by Secondary Immunodeficiency Disease, by Region, 2020-2034 (USD Billion)
7. Subcutaneous Immunoglobulin Market, By End Use
7.1. Key Findings
7.2. Introduction
7.2.1. Subcutaneous Immunoglobulin Market, By End Use, by Region, 2020-2034 (USD Billion)
7.3. Hospitals
7.3.1. Subcutaneous Immunoglobulin Market, by Hospitals, by Region, 2020-2034 (USD Billion)
7.4. Homecare
7.4.1. Subcutaneous Immunoglobulin Market, by Homecare, by Region, 2020-2034 (USD Billion)
7.5. Clinics
7.5.1. Subcutaneous Immunoglobulin Market, by Clinics, by Region, 2020-2034 (USD Billion)
7.6. Others
7.6.1. Subcutaneous Immunoglobulin Market, by Others, by Region, 2020-2034 (USD Billion)
8. Subcutaneous Immunoglobulin Market, by Geography
8.1. Key Findings
8.2. Introduction
8.2.1. Subcutaneous Immunoglobulin Market Assessment, By Geography, by Region, 2020-2034 (USD Billion)
8.3. Subcutaneous Immunoglobulin Market - North America
8.3.1. North America: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.3.2. North America: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.3.3. North America: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.3.4. Subcutaneous Immunoglobulin Market - US
8.3.4.1. US: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.3.4.2. US: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.3.4.3. US: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.3.5. Subcutaneous Immunoglobulin Market - Canada
8.3.5.1. Canada: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.3.5.2. Canada: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.3.5.3. Canada: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.4. Subcutaneous Immunoglobulin Market - Europe
8.4.1. Europe: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.4.2. Europe: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.4.3. Europe: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.4.4. Subcutaneous Immunoglobulin Market - UK
8.4.4.1. UK: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.4.4.2. UK: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.4.4.3. UK: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.4.5. Subcutaneous Immunoglobulin Market - France
8.4.5.1. France: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.4.5.2. France: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.4.5.3. France: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.4.6. Subcutaneous Immunoglobulin Market - Germany
8.4.6.1. Germany: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.4.6.2. Germany: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.4.6.3. Germany: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.4.7. Subcutaneous Immunoglobulin Market - Italy
8.4.7.1. Italy: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.4.7.2. Italy: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.4.7.3. Italy: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.4.8. Subcutaneous Immunoglobulin Market - Spain
8.4.8.1. Spain: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.4.8.2. Spain: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.4.8.3. Spain: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.4.9. Subcutaneous Immunoglobulin Market - Netherlands
8.4.9.1. Netherlands: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.4.9.2. Netherlands: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.4.9.3. Netherlands: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.4.10. Subcutaneous Immunoglobulin Market - Russia
8.4.10.1. Russia: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.4.10.2. Russia: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.4.10.3. Russia: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.4.11. Subcutaneous Immunoglobulin Market - Rest of Europe
8.4.11.1. Rest of Europe: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.4.11.2. Rest of Europe: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.4.11.3. Rest of Europe: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.5. Subcutaneous Immunoglobulin Market - Asia Pacific
8.5.1. Asia Pacific: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.5.2. Asia Pacific: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.5.3. Asia Pacific: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.5.4. Subcutaneous Immunoglobulin Market - China
8.5.4.1. China: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.5.4.2. China: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.5.4.3. China: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.5.5. Subcutaneous Immunoglobulin Market - India
8.5.5.1. India: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.5.5.2. India: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.5.5.3. India: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.5.6. Subcutaneous Immunoglobulin Market - Malaysia
8.5.6.1. Malaysia: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.5.6.2. Malaysia: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.5.6.3. Malaysia: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.5.7. Subcutaneous Immunoglobulin Market - Japan
8.5.7.1. Japan: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.5.7.2. Japan: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.5.7.3. Japan: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.5.8. Subcutaneous Immunoglobulin Market - Indonesia
8.5.8.1. Indonesia: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.5.8.2. Indonesia: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.5.8.3. Indonesia: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.5.9. Subcutaneous Immunoglobulin Market - South Korea
8.5.9.1. South Korea: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.5.9.2. South Korea: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.5.9.3. South Korea: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.5.10. Subcutaneous Immunoglobulin Market - Australia
8.5.10.1. Australia: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.5.10.2. Australia: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.5.10.3. Australia: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.5.11. Subcutaneous Immunoglobulin Market - Rest of Asia Pacific
8.5.11.1. Rest of Asia Pacific: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.5.11.2. Rest of Asia Pacific: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.5.11.3. Rest of Asia Pacific: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.6. Subcutaneous Immunoglobulin Market - Middle East & Africa
8.6.1. Middle East & Africa: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.6.2. Middle East & Africa: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.6.3. Middle East & Africa: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.6.4. Subcutaneous Immunoglobulin Market - Saudi Arabia
8.6.4.1. Saudi Arabia: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.6.4.2. Saudi Arabia: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.6.4.3. Saudi Arabia: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.6.5. Subcutaneous Immunoglobulin Market - UAE
8.6.5.1. UAE: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.6.5.2. UAE: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.6.5.3. UAE: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.6.6. Subcutaneous Immunoglobulin Market - Israel
8.6.6.1. Israel: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.6.6.2. Israel: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.6.6.3. Israel: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.6.7. Subcutaneous Immunoglobulin Market - South Africa
8.6.7.1. South Africa: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.6.7.2. South Africa: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.6.7.3. South Africa: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.6.8. Subcutaneous Immunoglobulin Market - Rest of Middle East & Africa
8.6.8.1. Rest of Middle East & Africa: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.6.8.2. Rest of Middle East & Africa: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.6.8.3. Rest of Middle East & Africa: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.7. Subcutaneous Immunoglobulin Market - Latin America
8.7.1. Latin America: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.7.2. Latin America: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.7.3. Latin America: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.7.4. Subcutaneous Immunoglobulin Market - Mexico
8.7.4.1. Mexico: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.7.4.2. Mexico: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.7.4.3. Mexico: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.7.5. Subcutaneous Immunoglobulin Market - Brazil
8.7.5.1. Brazil: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.7.5.2. Brazil: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.7.5.3. Brazil: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.7.6. Subcutaneous Immunoglobulin Market - Argentina
8.7.6.1. Argentina: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.7.6.2. Argentina: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.7.6.3. Argentina: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
8.7.7. Subcutaneous Immunoglobulin Market - Rest of Latin America
8.7.7.1. Rest of Latin America: Subcutaneous Immunoglobulin Market, by Product Type, by Region, 2020-2034 (USD Billion)
8.7.7.2. Rest of Latin America: Subcutaneous Immunoglobulin Market, by Application, by Region, 2020-2034 (USD Billion)
8.7.7.3. Rest of Latin America: Subcutaneous Immunoglobulin Market, by End Use, by Region, 2020-2034 (USD Billion)
9. Competitive Landscape
9.1. Expansion and Acquisition Analysis
9.1.1. Expansion
9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
10.1. Baxter
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Recent Development
10.2. Biotest
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Benchmarking
10.2.4. Recent Development
10.3. CSL Behring
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Benchmarking
10.3.4. Recent Development
10.4. GC Biopharma USA, Inc.
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Benchmarking
10.4.4. Recent Development
10.5. Grifols
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Product Benchmarking
10.5.4. Recent Development
10.6. Kamada Ltd.
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Benchmarking
10.6.4. Recent Development
10.7. LFB
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Product Benchmarking
10.7.4. Recent Development
10.8. Nufactor
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Benchmarking
10.8.4. Recent Development
10.9. Octapharma
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Product Benchmarking
10.9.4. Recent Development
10.10. Takeda
10.10.1. Company Overview
10.10.2. Financial Performance
10.10.3. Product Benchmarking
10.10.4. Recent Development